Literature DB >> 7114923

Lymphocyte cytotoxicity in systemic sclerosis: no increase on short-term culture with established human cell lines.

J K Wright, P Hughes, N R Rowell.   

Abstract

Lymphocyte cytotoxicity towards 4 established human epithelial and fibroblast cell lines was investigated in 18 patients with systemic sclerosis by means of both whole blood and peripheral blood mononuclear cells in short term (18 h) Cr-release assays. No difference in the levels of cytotoxicity was found in patients compared with 25 normal controls, even when allowance was made for the severity of the disease and the sex of patients and controls. It is suggested that long-term (3-6 days) culture may be necessary to demonstrate the increased lymphocyte cytotoxicity originally described in the disorder.

Entities:  

Mesh:

Year:  1982        PMID: 7114923      PMCID: PMC1000961          DOI: 10.1136/ard.41.4.414

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  13 in total

1.  ANTINUCLEAR AND PRECIPITATING AUTOANTIBODIES IN PROGRESSIVE SYSTEMIC SCLEROSIS.

Authors:  J S BECK; J R ANDERSON; K G GRAY; N R ROWELL
Journal:  Lancet       Date:  1963-12-07       Impact factor: 79.321

2.  Immunological aspects of systemic sclerosis in vitro activity of lymphocytes from patients with the disorder.

Authors:  S Currie; M Saunders; M Knowles
Journal:  Br J Dermatol       Date:  1971-05       Impact factor: 9.302

3.  Localized scleroderma-like lesions after bone marrow transplantation in man. A chronic graft versus host reaction.

Authors:  W A Van Vloten; E Scheffer; L J Dooren
Journal:  Br J Dermatol       Date:  1977-04       Impact factor: 9.302

4.  Cutaneous antigen-stimulating lymphokine production by lymphocytes of patients with progressive systemic sclerosis (scleroderma).

Authors:  H Kondo; B S Rabin; G P Rodnan
Journal:  J Clin Invest       Date:  1976-12       Impact factor: 14.808

5.  Serum antinuclear antibodies in progressive systemic sclerosis (scleroderma).

Authors:  N F Rothfield; G P Rodnan
Journal:  Arthritis Rheum       Date:  1968-10

6.  Destruction of human cells in tissue culture by lymphocytes from patients with systemic lupus erythematosus.

Authors:  T G Trayanova; V V Sura; G J Svet-Moldavsky
Journal:  Lancet       Date:  1966-02-26       Impact factor: 79.321

7.  Target selectivity of interferon-induced human killer lymphocytes related to their Fc receptor expression.

Authors:  M G Masucci; G Masucci; E Klein; W Berthold
Journal:  Proc Natl Acad Sci U S A       Date:  1980-06       Impact factor: 11.205

8.  Uracil-specific anti-R.N.A. antibodies in scleroderma.

Authors:  D Alarcón-Segovia; E Fishbein; E García-Ortigoza; S Estrada-Parra
Journal:  Lancet       Date:  1975-02-15       Impact factor: 79.321

9.  Spontaneous cell-mediated cytotoxicity in humans. Distribution and characterization of the effector cell.

Authors:  D Santoli; G Trinchieri; L Moretta; C M Zmijewski; H Koprowski
Journal:  Clin Exp Immunol       Date:  1978-08       Impact factor: 4.330

10.  Antibody-dependent and phytohaemagglutinin-induced lymphocyte cytotoxicity in systemic sclerosis.

Authors:  J K Wright; P Hughes; N R Rowell; I B Sneddon
Journal:  Clin Exp Immunol       Date:  1979-04       Impact factor: 4.330

View more
  3 in total

Review 1.  Natural killer cells and autoimmunity.

Authors:  E Grunebaum; E Malatzky-Goshen; Y Shoenfeld
Journal:  Immunol Res       Date:  1989       Impact factor: 2.829

2.  The differential responses of human skin and synovial fibroblasts to stanozolol in vitro: production of prostaglandin E2 and matrix metalloproteinases.

Authors:  A J Ellis; J K Wright; T E Cawston; B L Hazleman
Journal:  Agents Actions       Date:  1992-03

3.  The differential effects of stanozolol on human skin and synovial fibroblasts in vitro: DNA synthesis and receptor binding.

Authors:  A J Ellis; T E Cawston; E J Mackie
Journal:  Agents Actions       Date:  1994-03
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.